AR and prostate neoplasm: In contrast to well-documented mechanisms of adaptive resistance involving AR point mutations or amplification after long-term exposure to ADT (27–29), a subset of aggressive prostate tumors displays resistance to ADT as measured by transcriptional profiling of the tumor to have lower AR activity (24, 30, 31).